tbuckley/cabot-search huggingface dataset:
A prospective safety‐monitoring study of immunotherapy in mite‐allergy patients with mass‐units‐standardized extract
Authors: C. González de la Cuesta, R. Feijoo, P. Rico
Journal: Allergy (1997)

González de la Cuesta C, Feijoo R, Rico P. A prospective safety‐monitoring study of immunotherapy in mite‐allergy patients with mass‐units‐standardized extract. To determine the tolerance of an allergen extract standardized in mass units, we closely monitored the side‐effects, during the buildup phase of immunotherapy treatment, in 88 patients with well‐documented respiratory allergy to house‐dust mite ‘Dermatophagoides pteronyssinus’. Thirty‐four patients ‘38.6%’ suffered from moderate perennial rhinitis, and 54 had mild to moderate bronchial asthma ‘61.4%’. For the desensitizing treatment, we used a depot extract adsorbed in aluminum hydroxide of D. pteronyssinus ‘Pangramin® Depot UM’, biologically standardized and having the major allergens Der p 1 and Der p 2 quantified in micrograms. A total of 1244 doses were administered. All patients except one ‘98.9%’ reached the expected maximum dose of 4 μg Der p 1. Only five patients suffered mild adverse reactions ‘5.7%’. All adverse reactions except one appeared to be related to the vial of maximum concentration: vial III ‘4 μg Der p 1’. Considering the number of patients who had adverse reactions and the frequency of adverse reactions per dose, we found no significant differences between rhinitis and asthma sufferers. We think that immunotherapy in doses of 4 μg Der p 1 and 2 μg Der p 2 is well tolerated and should not be avoided in mildly to moderately asthmatic patients when treating house‐dust mite allergy.
Human IL4I1 is a secreted l-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation
Authors: Marie-Laure Boulland, Jeanine Marquet, Valérie Molinier-Frenkel, Peter Möller, Chrystelle Guiter, Fanette Lasoudris, Christiane Copie-Bergman, Maryse Baia, Philippe Gaulard, Karen Leroy, Flavia Castellano
Journal: Blood (2007)
Sjögren's syndrome in patients with primary biliary cirrhosis
Authors: Epaminondas V. Tsianos, Jay H. Hoofnagle, Philip C. Fox, Margaret Alspaugh, Anthony E. Jones, Daniel F. Schafer, Haralampos M. Moutsopoulos
Journal: Hepatology (1990)

Symptomatology and objective findings of Sjögren's syndrome were evaluated in 38 consecutive patients with primary biliary cirrhosis. Symptoms of Sjögren's syndrome were present in 18 (47.4%) patients, but were severe enough to warrant therapy in only four (10.5%). Nineteen patients consented to evaluation for Sjögren's syndrome, which included Schirmer's I test, measurement of parotid flow rate and serum autoantibodies, labial minor salivary gland biopsy and human leukocyte antigen typing. Histological changes diagnostic of Sjögren's syndrome were present in five patients (26.3%). All five patients had symptoms of Sjögren's syndrome and three had abnormal Schirmer's I tests, but none had corneal ulcerations or decreased parotid flow rates. Results of serological tests and human leukocyte antigen typing were not similar to those described in patients with primary Sjögren's syndrome but were similar to those described in patients with rheumatoid arthritis and Sjögren's syndrome. These findings indicate that Sjögren's syndrome associated with primary biliary cirrhosis is a form of secondary Sjögren's syndrome resembling that associated with rheumatoid arthritis.
Salivary Secretion of Blood Factors in Cancer
Authors: Crichton McNeil
Journal: JAMA (1968)

<h3>To the Editor:—</h3> This is a response to a paper entitled "Salivary Secretion of Blood-Group Factors in Cancer" by Krant et al (<b>204</b>:153, 1968). Dr. Krant has made rather Sweeping conclusions on inadequate material. Examination of Table 1, under column "lung," shows a rather startling skew in the number of sese (nonsecretory) patients listed as group O. Serologists and immunologists are aware of errors in H (O) secretion recognition with<i>Ulex europaeus</i>. Le<sup>a</sup>cell typing should be done to confirm the sese status. Since he shows a<i>34%</i>sese here I would suspect mistyping of secretion because if no significance existed we would expect<i>22.7%</i>. Under groups A, B, and AB, this does not show because they could check the secretor status with anti A or B or both to make a confirmation. Dr. Krant does not list a category of "survivors" so it is difficult to interpret
Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.
Authors: W F Lems, M I Gerrits, J W Jacobs, R M van Vugt, H J van Rijn, J W Bijlsma
Journal: Annals of the Rheumatic Diseases (1996)

OBJECTIVE: To examine the effect of high dose corticosteroid pulse treatment (three times 200 mg dexamethasone intravenously in eight days) on calcium and bone metabolism in 17 consecutive patients with active rheumatoid arthritis (RA). METHODS: Bone formation was quantified by measurement of serum alkaline phosphatase, osteocalcin, and carboxyterminal propeptide of type I procollagen (pro-I-CPP) concentrations. Bone resorption was measured by urinary excretion of calcium, hydroxyproline, (free and total) deoxypyridinoline (Dpyr), (free and total) pyridinoline (Pyr), and serum concentrations of the carboxyterminal cross linked telopeptide of type I collagen (I-CTP). Disease activity of RA was measured by erythrocyte sedimentation rate, C reactive protein, and Ritchie and Thompson joint scores. RESULTS: Disease activity was initially high, and decreased during corticosteroid pulse treatment and the following five weeks. Osteocalcin, alkaline phosphatase, and pro-I-CPP concentrations were initially within normal limits, while I-CTP, Dpyr, and Pyr were increased. Osteocalcin and pro-I-CPP concentrations decreased (p &lt; 0.01) during corticosteroid pulse treatment, but rapidly returned to baseline after the treatment. No changes were observed in alkaline phosphatase and urinary excretion of calcium and hydroxyproline. Bone resorption measured by serum I-CTP and urinary excretion of Pyr and Dpyr was unchanged or decreased (p &lt; 0.05-0.01), depending on the time of measurement and the parameter measured. CONCLUSIONS: In these patients with active RA, bone resorption was increased, while bone formation was within normal limits. During high dose corticosteroid pulse treatment, bone formation was only transiently decreased, while markers of bone resorption were unchanged or decreased. Because corticosteroid pulse treatment has only a short term negative effect on bone formation, and because it probably reduces bone resorption, at least partly as a result of the decreased disease activity, the effect of corticosteroid pulse treatment on bone may be assumed to be relatively mild.
Duodenal Myoelectric Activity in Scleroderma
Authors: Anthony J. DiMarino, Gerald Carlson, Allen Myers, H. Ralph Schumacher, Sidney Cohen
Journal: New England Journal of Medicine (1973)

To determine the pathogenesis of small-bowel motor dysfunction in scleroderma, myoelectric and pressure responses of the duodenum were recorded at rest and in response to the duodenal instillation of warm water and the injection of pentagastrin, secretin and cholecystokinin. Slow-wave frequency and propagation velocity were similar in controls and in patients with scleroderma. In controls, the rate of slow waves associated with spike bursts after duodenal instillation of water (mean ± S.E.) was 95.7 ± 4.8 per cent as compared to 20.1 ± 2.8 per cent in scleroderma (p<0.01). Secretin and pentagastrin but not cholecystokinin increased the percentage of slow waves associated with spike bursts in normal controls. Of patients with scleroderma, seven responded normally to secretin and pentagastrin whereas six showed no response. Those who did not respond had disease of longer duration, a dilated proximal duodenum and steatorrhea. These studies suggest that motor dysfunction of the small intestine in scleroderma may be a result of impaired activation by mechanical and hormonal stimuli. (N Engl J Med 289:1220–1223, 1973)
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection
Authors: Alessandra Mangia, Nicola Minerva, Donato Bacca, Raffaele Cozzolongo, Ernesto Agostinacchio, Fernando Sogari, Gaetano Scotto, Francesco Vinelli, Giovanni Luciano Ricci, Mario Romano, Vito Carretta, Daniela Petruzzellis, Angelo Andriulli
Journal: Hepatology (2008)

Abstract In hepatitis C virus (HCV) genotypes 2 and 3 patients, the high rate of relapse after 12 to 16 weeks of antiviral therapy is the main concern for shortening treatment duration. This study was undertaken to delineate predictors of relapse after short treatment in patients with undetectable HCV RNA at treatment week 4 (RVR), and to report in RVR patients with relapse the sustained virological response (SVR) after a second 24-week course of therapy. RVR patients received pegylated interferon (Peg-IFN) alfa-2b (1.5 μg/kg) and ribavirin (1000-1200 mg/day) for 12 weeks; those who relapsed were re-treated with the same drug doses but for the extended standard duration of 24 weeks. Logistic regression analysis was applied to delineate predictors of relapse by using age, sex, route of transmission, body mass index (BMI), serum alanine aminotransferase (ALT), HCV genotypes, serum HCV RNA levels, and platelet counts as covariates. Of 718 patients with genotypes 2 and 3 who were started on therapy, 496 (69.1%) had undetectable HCV RNA at week 4. Of them, 409 patients (82.5%, CI 79.1-85.8) attained SVR, and 67 (14.1%, CI 10.4-16.5) relapsed. At regression analysis, only platelet count less than 140,000 mm 3 [odds ratio, 2.51; confidence interval (CI), 1.49-4.20] and BMI 30 or higher (odds ratio, 1.7; CI, 1.03-2.70) were independently associated with relapse. Forty-three of 67 patients with relapse agreed to be re-treated, and an SVR was achieved in 30 (70.0%) of them. Conclusion: We recommend 12 weeks course of therapy for patients with undetectable HCV RNA at treatment week 4, providing they present with no advanced fibrosis and low BMI. (Hepatology 2008.)
Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase.
Authors: S N Tennant, J Dixon, T C Venable, H L Page, A Roach, A B Kaiser, R Frederiksen, L Tacogue, P Kaplan, N S Babu
Journal: Circulation (1984)

The efficacy of intracoronary urokinase and streptokinase were compared in 80 patients with acute myocardial infarction in a prospective, randomized, double-blind study. Urokinase was infused into the occluded coronary artery at 6000 U/min, and streptokinase was infused at 2000 U/min. Maximal duration of infusion was 2 hr. The frequency of successfully opening the artery was similar for patients receiving urokinase (27 of 45, 60%) and those receiving streptokinase (20 of 35, 57%). Fibrinogen levels after infusion were measured in 63 patients. Nineteen of 29 streptokinase recipients had fibrinogen levels less than 100 mg/dl compared with levels of two of 34 urokinase recipients (p less than .001). Five of 45 (11%) patients receiving urokinase and 10 of 35 receiving streptokinase (29%) had bleeding complications (p less than .05). Major bleeding after early coronary artery bypass surgery was more frequent in the streptokinase group (four of five compared with a similar group of patients receiving urokinase (none of five). This study demonstrates that while urokinase and streptokinase have equal intracoronary thrombolytic efficacy, patients receiving urokinase have less systemic fibrinolysis and less perioperative bleeding with early surgery than do patients receiving streptokinase.
Guidelines for drug donations
Authors: H V Hogerzeil, M R Couper, R Gray
Journal: BMJ (1997)

Drug donations are usually given in response to acute emergencies, but they can also be part of development aid. Donations may be given directly by governments, by non-governmental organisations, as corporate donations (direct or through private voluntary organisations), or as private donations to single health facilities. Although there are legitimate differences between these donations, basic rules should apply to them all. This common core of "good donation practice" is the basis for new guidelines which have recently been issued by the World Health Organisation after consultation with all relevant United Nations agencies, the Red Cross, and other major international agencies active in humanitarian emergency relief. This article summarises the need for such guidelines, the development process, the core principles, and the guidelines themselves and gives practical advice to recipients and donor agencies.
Insidious reintroduction of wild poliovirus into Israel, 2013
Authors: E Anis, E Kopel, S R Singer, E Kaliner, L Moerman, J Moran-Gilad, D Sofer, Y Manor, L M Shulman, E Mendelson, M Gdalevich, B Lev, R Gamzu, I Grotto
Journal: Eurosurveillance (2013)

Israel was certified as polio-free country in June 2002, along with the rest of the World Health Organization European Region. Some 11 years later, wild-type polio virus ₁ (WPV₁) was isolated initially from routine sewage samples collected between 7 and 13 April 2013 in two cities in the Southern district. WPV₁-specific analysis of samples indicated WPV₁ introduction into that area in early February 2013. National supplementary immunisation with oral polio vaccine has been ongoing since August 2013.
CERVICAL PAPILLOMAVIRUS INFECTION PROGRESSING TO INVASIVE CANCER IN LESS THAN THREE YEARS
Authors: Kari Syrjanen, Ethel-Michele De Villiers, Seppo Saarikoski, Olli Castren, Martti Väyrynen, Rauno Mantyjarvi, Sinikka Parkkinen
Journal: The Lancet (1985)
OBSERVATIONS ON CASTELLANI'S "TETRAVACCINE" AND "PENTAVACCINE."
Authors: G. A. Lurie
Journal: BMJ (1916)

A U ~~~~~~~~~~~~~MD I C A L JOUNIIAS 4 at the Cardiff Infirmary, and it-was through the accident of my going into the ward during visiting hours and sQeing hiim converse with his wife in the deaf-anid-dtumb language that I obtained his singular history.He was one of.tlle few survivors in a big colliery explosion.He remembered nothing of the accident, btA on recovering consciousness found that he could neitlher lhear a sound nor articulate a word.After remaining, in this condition for a considerable timne lhe went to a school for the deaf and dumb, and eventually married a congenital deaf-mute.He lived happily in tilis state for some years, and resumed work until the occurrence of a second under- ground explosion, which was followed by hiis recovery fromn deaf-mutism; he stated that he distinctly remembered "hearing the ground tremble" before lapsiiig into uicoin- sciousness whiclh lasted a few days.Wlhen hie regained consciousness lhe got very excited upon discovering that his powers of speeclh and hearing lhad returned.Tl'he late Dr. Naunton Davies, J.P., of Portl), told me that lhe knew the nman well, and that in hlis opinion there was a strong lhysterical strain in hiim; Dr. Davies said also that there was no evidence of direct injury to the head.The present war lhas added to our knowledge of the causation of symptoms which are clinically so well known, and are described in the textbooks in chiapters on con- cussion of tlhe brain.It is no longer necessary to assurne
1063-59 Preprocedural statin medication reduces the risk for periprocedural myocardial infarctions in patients with stent implantation independent of the cholesterol level
Authors: Michael Haude, Joerg Herrmann, Lothar Volbracht, Thomas Konorza, Christoph Altmann, Rainer Schulz, Gerd Heusch, Raimund Erbel
Journal: Journal of the American College of Cardiology (2004)
HIGHER MEDICAL EDUCATION.
Authors: W. M. HARSHA
Journal: JAMA (1892)

Higher medical education was discussed at the meeting of the South Side Medical Club, October 28, last.  President Harper, of the Chicago University, had expected to be present but was prevented, much to the disappointment of the members of the club.  The principal speaker of the evening was Prof. Wm. E. Quine, a recognized leader in the movement toward higher medical education, who in his usual interesting and impressive manner, traced the advances made in medical teaching during the past two decades. He showed conclusively that the progress has come through the efforts of medical teachers of the more progressive schools, rather than through the demands of the profession at large, or of the public or even of State boards of health. The higher standard of preliminary education now obtaining among medical students was noted among the encouraging signs; and the establishment of an increased number of chairs, and of
Jonas Edward Salk, MD
Authors: William H. Foege
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manic-Depressive Disease: A Case History
Authors: John Campbell
Journal: JAMA (1970)

To the Editor.—  For 96 years recurrent depressions occurred in a woman who lived to be 103 years. The Figure is a chart of these depressions, compiled from the records of Johns Hopkins Hospital, Dr. Foster Kennedy's office, and the author's files.  Report of a Case.—  Born in 1866, the patient developed her first brief depression at age 7 years, and at age 14 years a second occurred. During the next few years no definite depressions recurred until 1904, after her marriage, when she had her first serious episode followed closely by two additional attacks.  In 1961, she was treated at the Henry Phipps Institute, Johns Hopkins Hospital, for the fourth serious depression. It was at this time that her brother died of paresis, having been one of the first patients treated for malaria at Johns Hopkins in 1916. One sister also had a depression at age 35 years,
Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints
Authors: Aaron S. Kesselheim, Michelle M. Mello, David M. Studdert
Journal: PLoS Medicine (2011)

Aaron Kesselheim and colleagues analyzed unsealed whistleblower complaints against pharmaceutical companies filed in US federal fraud cases that contained allegations of off-label marketing, and develop a taxonomy of the various off-label practices.
Delivery after caesarean section: review of 2176 consecutive cases.
Authors: B G Molloy, O Sheil, N M Duignan
Journal: BMJ (1987)

A total of 2176 consecutive patients who had had one previous caesarean section were studied retrospectively. A repeat elective caesarean section was performed in 395 (18.2%). Labour started spontaneously in 1363 patients, 301 of whom were given oxytocin to accelerate inert labour, and was induced by amniotomy and infusion of oxytocin in 418 women; 1618 of these 1781 patients (90.8%) delivered vaginally. Patients who had had a previous vaginal delivery were more likely to deliver vaginally again. Those women in whom the initial caesarean section had been performed during labour before the cervix was 4 cm dilated were less likely to deliver vaginally than those who had progressed further in labour or those who had had an elective caesarean section. Similarly, those who received oxytocin to stimulate inert labour were more likely to require a repeat caesarean section than those who did not. The uterine scar ruptured in only eight (0.45%) of the 1781 patients allowed into labour. The risk of rupture of the scar was not increased by the use of oxytocin alone either to induce or to accelerate labour. The combination of oxytocin to accelerate labour and epidural analgesia to provide pain relief, however, was associated with an increased incidence of scar rupture. Labour may be safely allowed in women who have had a previous caesarean section, most of whom will deliver vaginally. Induction of labour does not increase the risk of either a repeat caesarean section or rupture of a uterine scar.
Sodium nuclear magnetic resonance imaging of acute cardiac rejection in heterotopic heart transplantation
Authors: T. NISHIMURA, M. SADA, H. SASAKI, N. YAMADA, Y. YAMADA, C. YUTANI, H. AMEMIYA, T. FUJITA, T. AKUTSU, H. MANABE
Journal: Cardiovascular Research (1989)

Nuclear magnetic resonance (NMR) imaging was used to measure tissue sodium-23 in the myocardium undergoing cardiac rejection. In six dogs, the donor heart was heterotopically transplanted into the recipient's chest cavity. The dogs were then killed and sodium-23 images of the excised hearts were obtained using a high field (1.5 Tesla) NMR imaging system. Proton NMR imaging of each excised heart was also performed and T1, T2 relaxation times were calculated. Subsequently, these data were correlated with pathological findings of mild, moderate and severe rejection. The correlation coefficients between the rejection score and the T1, T2 relaxation times and sodium NMR signal intensity were 0.79, 0.70 and 0.84, respectively. Severely rejected areas of the myocardium were visualised by increased sodium NMR signals. These findings suggest that an increase of sodium NMR intensity is mainly caused by an increase of intracellular sodium content due to irreversible myocardial necrosis. Sodium NMR allows evaluation of the location and extent of rejection of myocardium after heart transplantation.
Long-term recovery of diaphragm strength in neuralgic amyotrophy
Authors: PD Hughes, MI Polkey, J Moxham, M Green
Journal: European Respiratory Journal (1999)

Diaphragm paralysis is a recognized complication of neuralgic amyotrophy that causes severe dyspnoea. Although recovery of strength in the arm muscles, when affected, is common, there are little data on recovery of diaphragm function. This study, therefore, re-assessed diaphragm strength in cases of bilateral diaphragm paralysis due to neuralgic amyotrophy that had previously been diagnosed at the authors institutions. Fourteen patients were recalled between 2 and 11 yrs after the original diagnosis. Respiratory muscle and diaphragm strength were measured by volitional manoeuvres as maximal inspiratory pressure and sniff transdiaphragmatic pressure. Cervical magnetic phrenic nerve stimulation was used to give a nonvolitional measure of diaphragm strength: twitch transdiaphragmatic pressure. Only two patients remained severely breathless. Ten of the 14 patients had evidence of some recovery of diaphragm strength, in seven cases to within 50% of the lower limit of normal. The rate of recovery was variable: one patient had some recovery after 2 yrs, and the rest took 3 yrs or more. In conclusion, in most patients with diaphragm paralysis due to neuralgic amyotrophy, some recovery of the diaphragm strength occurs, but the rate of recovery may be slow.